Emergent data influences the risk/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus
After decades of investigation, gene therapy has received regulatory approval to treat hemophilia. However, since gene therapy investigations were initially conceived, other avenues of treatment have revolutionized the care of hemophilia. Emergent data is showing that gene therapy may not be as bene...
Main Author: | John Puetz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1256919/full |
Similar Items
-
“Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A Study of 276 Patients in Western India
by: Sangita Darshan Shah, et al.
Published: (2019-01-01) -
Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
by: Anshu Shrestha, et al.
Published: (2021-01-01) -
Clinical profile and demographic characteristics of moderate and severe hemophilia patients in a tertiary care hospital of Bangladesh
by: Mohammed Nadimul Islam, et al.
Published: (2022-07-01) -
Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction
by: Junjiang Sun, et al.
Published: (2022-08-01) -
Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
by: Tine M.H.J. Goedhart, et al.
Published: (2022-01-01)